Login
$PTCT
$60.97 -$2.52 (3.97%) Live

$PTCT SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
16 Nov 2026 144
16 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 SCHEDULE 13G
03 Nov 2026 8-K: Regulation FD Disclosure; Other Events

WARREN, N.J., Nov. 3, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of the Company’s outstanding shar...

29 Oct 2026 10-Q
29 Oct 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue –

16 Oct 2026 Form 4: Schmertzler Michael, Director

Sold 2,500 shares ($149K)

13 Oct 2026 Form 4: Boulding Mark Elliott, EXEC. VP AND CLO

Received 192 shares by exercise or conversion ($7.57K) · Sold 192 shares ($12.3K)

09 Oct 2026 Form 4: Schmertzler Michael, Director

Sold 2,500 shares ($158K)

09 Oct 2026 144
07 Oct 2026 Form 4: Boulding Mark Elliott, EXEC. VP AND CLO

Received 1,638 shares by exercise or conversion ($64.6K) · Sold 1,638 shares ($105K) · Received 435 shares by exercise or conversion ($17.1K) · 1 more

07 Oct 2026 144
06 Oct 2026 144
05 Oct 2026 144
02 Oct 2026 Form 4: Steele Glenn Jr Md Phd, Director

Received 12,000 shares by exercise or conversion ($135K) · Sold 12,000 shares ($782K)

30 Sep 2026 144
21 Sep 2026 8-K: Regulation FD Disclosure; Other Events

WARREN, N.J., Sept. 21, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene th...

18 Sep 2026 Form 4: Schmertzler Michael, Director

Sold 10,000 shares ($671K) · Sold 10,000 shares ($679K)

11 Sep 2026 Form 4: Schmertzler Michael, Director

Sold 10,000 shares ($678K) · Sold 10,000 shares ($673K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support